skip to Main Content

Dr. Hidalgo Medina on the Rationale for Using Patient-Derived Organoids in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.

In the HOPE study, investigators tested the use of PDOs to predict a patient’s response to treatment, says Hidalgo Medina. Results from the study indicated that PDOs could help personalize therapy for patients with pancreatic cancer and ultimately, spare them the toxicities that are associated with ineffective treatments. Read more . . . 


Back To Top